Important role of human capital in national production
The four new high technical drugs for treating cancer and diabetes were unveiled on Tuesday 7th of May 2019, at a ceremony attended by Dr. Sorena Sattari, the Vice President of Science and Technology of the President, Dr. Saeed Namaki, Minister of Health and Medical Education, Dr. Ghanei, secretary of the department of biotechnology development of vice Presidency of Technology, and Dr. Abbas Kebriaee zadeh, director of the department of economics and pharmaceutical management of Tehran University of Medical Sciences, at the Dakpha Pharmaceutical holding Group in Eshtehard Industrial Park, Alborz province.
The anti-cancer drugs are being developed and commercialized by the researchers of the Baran chemical and Pharmaceutical Company, and anti-diabetics drugs by researchers of Alborz pharmed pharmaceutical company in Eshtehard Industrial Estate, Alborz province, this movement is an effective step in the treatment of certain diseases, and introduction of the ability and creativity of Iranian scientists, saving money and helping the economy of the country.
Also, these drugs include “Sorafenib” and “Regorafenib” for the treatment of cancer, and “Empagliflozin” and “Dapagliflozin” the new generation of drugs for treatment of type 2 diabetes, which have less side effects of previous medications.
Dr. Namaki stated: “Development means the transformation of manpower into human capital. The human capital plays a role in national production.”
Dr. Namaki continued: “In the Ministry of Health, our policy is to support domestic production. We do not allow the import of drugs and raw materials produced in our country.” He added that this method of supporting domestic production calls for a solidarity. We all need to help each other on the national level and provide support in the field of production and supply.
The Minister of Health commented on cancer drugs: “We are pursuing two policies: first, prevention and lifestyle modification, and second, the development of medicines needed in the country.”
Dr Sorena Sattari said: “This year we will have a joint program for pharmaceutical raw materials in cooperation with the Food and Drug.” Dr. Sattari highlighted the potential of Iranian pharmaceutical companies. “There are great things to do with the researchers in the pharmaceutical industry,” he said. Also He added: “The ecosystem of the Alborz province is also a great potential that we can use these capacities and turn Alborz into a pharmaceutical hub in Iran.”
Dr. Kebriaee Zadeh said: “I thank the provincial directors who helped build the infrastructure in the country.” He mentioned the idea of working on new molecules began in the year 83 and a team was formed in this direction.
Dr. Kebriaee Zadeh continued: “The first drug was an oral medication for thalassemic patients, which in the year 86 was the first generic device for this drug. At the suggestion of the Ministry of Health, our approach was to deepen knowledge. In 2011, we decided to focus on the production of anticancer drugs, and fortunately in the year 2016, we completed the formulation. “He said.Dr. Kebriaee zadeh also added: “With an open and smart look of Dr. Ghanei, we have targeted 25 new formulations.””I hope we can make God and martyrs happy with our efforts,” he said.
